How has been the historical performance of Remus Pharma.?

Answer:The historical performance of Remus Pharma shows significant growth from the fiscal year ending March 2024 to March 2025.

Breakdown:
In the fiscal year ending March 2025, Remus Pharma reported net sales of 620.36 Cr, a substantial increase from 212.94 Cr in March 2024. The total operating income mirrored this growth, reaching 620.36 Cr compared to 212.94 Cr the previous year. Total expenditure also rose to 574.67 Cr from 183.98 Cr, with notable increases in the purchase of finished goods and other expenses. Operating profit (PBDIT) increased to 50.67 Cr from 31.79 Cr, while profit before tax rose to 47.34 Cr from 30.17 Cr. The profit after tax also saw an increase, reaching 38.42 Cr compared to 24.28 Cr in the prior year. The consolidated net profit for March 2025 was 29.07 Cr, up from 20.52 Cr. Earnings per share improved significantly to 24.68 from 17.45, and the book value per share adjusted to 217.2 from 134.09. On the balance sheet, total assets increased to 432.64 Cr from 333.11 Cr, and total liabilities rose to 432.64 Cr from 333.11 Cr. Cash flow from operating activities improved to 6.00 Cr from 1.00 Cr, contributing to a closing cash and cash equivalent of 7.00 Cr, up from 4.00 Cr. Overall, these metrics indicate a strong upward trend in Remus Pharma's financial performance over the year.